Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (2377)
All Articles published online
|
Aug 14, 2007 (publication date) through Nov 8, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Chae HB, Hann HW. Baseline HBV DNA level is the most important factor associated with virologic breakthrough in chronic hepatitis B treated with lamivudine. World J Gastroenterol 2007; 13(30): 4085-4090 [PMID: 17696226 DOI: 10.3748/wjg.v13.i30.4085] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v13/i30/4085.htm |
| Number | Citing Articles |
| 1 |
Hie-Won Hann, Vicki L. Gregory, Jonathan S. Dixon, Keith F. Barker. A review of the one-year incidence of resistance to lamivudine in the treatment of chronic hepatitis B. Hepatology International 2008; 2(4): 440 doi: 10.1007/s12072-008-9105-y
|
| 2 |
Man-Fung Yuen, James Fung, Danny Ka-Ho Wong, Ching-Lung Lai. Prevention and management of drug resistance for antihepatitis B treatment. The Lancet Infectious Diseases 2009; 9(4): 256 doi: 10.1016/S1473-3099(09)70056-8
|
| 3 |
Erica Villa, Barbara Lei, Gloria Taliani, Amalia Graziosi, Rosina Critelli, Monica Luongo, William Gennari, Marcello Bianchini, Ilva Ferretti. Pretreatment with Pegylated Interferon Prevents Emergence of Lamivudine Mutants in Lamivudine-Naive Patients: A Pilot Study. Antiviral Therapy 2009; 14(8): 1081 doi: 10.3851/IMP1465
|
| 4 |
Juan Wang, Ling-yao Du, Xia Zhu, En-qiang Chen, Hong Tang. The predictive value of early indicators for HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients with Telbivudine treatment for 104 weeks. Indian Journal of Medical Microbiology 2015; 33: S20 doi: 10.4103/0255-0857.148827
|
| 5 |
Hyung Joon Yim, Seong Gyu Hwang. Options for the management of antiviral resistance during hepatitis B therapy: reflections on battles over a decade. Clinical and Molecular Hepatology 2013; 19(3): 195 doi: 10.3350/cmh.2013.19.3.195
|
| 6 |
Shahinul Alam, Golam Azam, Golam Mustafa, Nooruddin Ahmad, Belalul Islam, Provat Kumar Podder, Mobin Khan. Pretreatment and on-treatment predictors of viral breakthrough in lamivudine therapy for chronic hepatitis B. Hepatology International 2008; 2(4): 494 doi: 10.1007/s12072-008-9095-9
|
| 7 |
Jesse Civan, Hie Won Hann. Giving rituximab in patients with occult or resolved hepatitis B virus infection: are the current guidelines good enough?. Expert Opinion on Drug Safety 2015; 14(6): 865 doi: 10.1517/14740338.2015.1032243
|
| 8 |
Rui Yu, Rong Fan, Jinlin Hou. Chronic hepatitis B virus infection: epidemiology, prevention, and treatment in China. Frontiers of Medicine 2014; 8(2): 135 doi: 10.1007/s11684-014-0331-5
|
| 9 |
Nicholas Noverati, Vivian Yan, Jay W. Jun, Dina Halegoua-DeMarzio, Hie-Won Hann. The Long Game: A Functional Cure Is Possible with Nucleoside Analogues and the Tincture of Time. Livers 2023; 3(3): 325 doi: 10.3390/livers3030024
|
| 10 |
Ki Bae Bang, Hong Joo Kim. Management of antiviral drug resistance in chronic hepatitis B. World Journal of Gastroenterology 2014; 20(33): 11641-11649 doi: 10.3748/wjg.v20.i33.11641
|
| 11 |
Lanish Singh, Trevor Graham Bell, Mukhlid Yousif, Anna Kramvis. Response of hepatitis B virus to antiretroviral treatment containing lamivudine in HBsAg‐positive and HBsAg‐negative HIV‐positive South African adults. Journal of Medical Virology 2019; 91(5): 758 doi: 10.1002/jmv.25375
|
| 12 |
Guvenc Kockaya, Akin Kose, Fatma Betul Yenilmez, Oktay Ozdemir, Ece Kucuksayrac. Cost-effectiveness analysis of oral anti-viral drugs used for treatment of chronic hepatitis B in Turkey. Cost Effectiveness and Resource Allocation 2015; 13(1) doi: 10.1186/s12962-015-0046-8
|
| 13 |
Xue-Jie Wu, Yan Wang, Ji Chen, Gui-Qiang Wang. Baseline predictors of virological response for chronic hepatitis B patients. World Journal of Gastroenterology 2009; 15(34): 4311-4315 doi: 10.3748/wjg.15.4311
|
| 14 |
Julien Lupo, Sylvie Larrat, Marie-Noëlle Hilleret, Raphaële Germi, Véronique Boyer, Sandrine Nicod, Gérard Barguès, Vincent Leroy, Jean-Marie Seigneurin, Jean-Pierre Zarski, Patrice Morand. Assessment of selective real-time PCR for quantitation of lamivudine and adefovir hepatitis B virus-resistant strains and comparison with direct sequencing and line probe assays. Journal of Virological Methods 2009; 156(1-2): 52 doi: 10.1016/j.jviromet.2008.10.028
|
| 15 |
Jörg Petersen, Maria Buti. Considerations for the long-term treatment of chronic hepatitis B with nucleos(t)ide analogs. Expert Review of Gastroenterology & Hepatology 2012; 6(6): 683 doi: 10.1586/egh.12.52
|